Mfd. by :- Sanofi (Fulfilled By : Magicine Pharma)
Magicine Pharma is registered with the Government Of NCT, India, Ministry Of Health in Government of Delhi, India, registration number DL-RAJ-122372 and as a wholesale distributor, department file No. 44208.
Brand Name:- Libtayo
Generic Name:- Cemiplimab-rwlc
Strength:- 350mg/7ml (50mg/ml)
Indication:- Skin Cancer
Storage:- Store at room temperature
Libtayo (Cemiplimab-rwlc) is used to treat a type of skin cancer that has spread to other areas of the body that cannot be treated with radiation or surgery. It is given as an infusion into the vein. Do not self administer this medicine. Take this medicine as prescribed by your medical advisor. Your doctor will decide the exact dosage. Do not take this medicine in the wrong way as it may lead to some severe side effects. It is advisable not to change or stop the dose without taking suggestions from your doctor. If you experience any symptoms while receiving this medicine, inform your doctor immediately.
Cemiplimab inhibits tumor growth by an immune-mediated mechanism, specifically by the inhibition of the programmed death receptor 1 (PD-1) treating cutaneous squamous cell carcinoma. 350mg IV over 30 minutes every 3 weeks until disease progression.
This medicine may cause some serious and unwanted side effects. It requires immediate medical attention otherwise it can also lead to higher risk. Discuss the risks and benefits of this medication with a medical advisor before starting the treatment.
Difficulty in urination
Pounding in the ears
Back or neck pain
Change in eyesight
Swelling in your ankles
Tingling of arms and legs
Note- Immediately contact your doctor if side effects occur.
Take this injection as prescribed by your doctor. Do not self administer. The injection is given as an infusion into your vein by a doctor or nurse.
It is advisable not to miss a dose. If you miss an appointment for a scheduled dose of this medicine, contact your doctor immediately.
In case of an overdose, the doctor will provide emergency medical treatment.
This medicine is used to treat a certain type of cancer (cutaneous squamous cell carcinoma) CSCC. This medication works by changing the action of the immune system and directing it to kill or stops the growth of cancer cells. Take this medicine according to your dosing schedule. This medicine must be given slowly, it takes at least 30 minutes to complete one infusion. The dose of medicine is decided by a medical advisor according to your response to the treatment and your previous medical condition. Cemiplimab is given once every 3 weeks. This medicine is not recommended for breastfeeding. Protect this medicine from heat and light. Do not shake or freeze the medicine.
Before starting treatment with Libtayo, please inform your doctor about your previous medical history. If you experience any symptoms while receiving this medication, do not ignore those symptoms because it may lead to higher risk.
Use effective methods of contraception to prevent pregnancy while taking this medicine.
Children and adolescents
This medicine is not advisable for use in children and adolescents.
Libtayo shouldn’t be used by pregnant women. Cemiplimab-rwlc may cause harm to the baby. It is recommended that this medicine should be avoided during pregnancy.
This medicine is not recommended in breastfeeding unless it is necessary. Please consult your medical advisor before starting treatment with this medication.
Do not receive any vaccine during your treatment with this medicine.
This medicine may cause immune-related problems.
A regular blood test is required to check the side effects.
Do not breastfeed while taking cemiplimab.
Avoid contact with people who have infections.
Libtayo can immune-mediated thyroid disorders.
Not safe for pregnant women.
Do not drive or operate heavy machinery.
Do not self administer this medicine.
Do not breastfeed while receiving this medication.
Ans. Libtayo (Cemiplimab-rwlc) is used to treat a certain type of skin cancer that has spread to other parts of the body or cannot be treated with radiation or surgery.
Ans. This medication works by changing the action of the immune system and directing it to kill or stop the growth of cancer cells. This medicine belongs to a class of drugs known as monoclonal antibodies.
Ans. This medicine is available in the strength of 350mg/7ml (50mg/ml).
Ans. Some common side effects are:- diarrhea, nausea, constipation, sore throat, fever, cough, skin rash, abdominal pain, pale skin, chest pain, irregular heartbeat, blurred vision, etc.
Ans. This medicine is given as an infusion into the vein. It is given once every 3 weeks. The infusion usually takes 30 minutes to complete.
Ans. Follow your doctor’s instructions about any restrictions on food or physical activities.
Ans. If you miss a scheduled dose of this medicine, contact your doctor immediately.
Ans. Keep yourself hydrated and maintain good nutrition.
Ans. It is not known whether it is safe or not. Please consult your doctor before consuming alcohol.
Ans. This medicine may decrease your ability to drive or affect your vision. Do not drive if any symptoms occur.
Ans. Please consult your doctor, before consuming this drug.
Ans. This medicine is not recommended for pregnant women.
Ans. This medicine is not recommended in breastfeeding unless it is necessary.
Ans. Store this medicine at room temperature. Do not shake or freeze the medicine.
Interactions may change how your medication works and increase the risk for side effects. Don’t forget to disclose your previous medical history with the doctor.
Interaction with alcohol is unknown. Please consult your doctor before consuming alcohol.
Libtayo injection is not recommended for use in patients with a known allergy to Cemiplimab-rwlc.
This medicine is contracted in patients known to be hypersensitive.